INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead to neurodegenerative...
CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...
DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...
H.C. Wainwright launched coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $2 price target. The stock closed at 57 cents on Aug. 29. TRACON is developing targeted therapeutics for cancer...
Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...
H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...
PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...
Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...
Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...
DelMar Pharmaceuticals (NASDAQ:DMPI) treated the first MGMT-unmethylated glioblastoma multiforme (GBM) patient in the adjuvant trial arm of its Phase 2 study of VAL-083. This study arm will enroll up to 24 newly...